Effect of Vitamin Supplementation in Glaucoma Patients

Glaucoma Clinical Trial

Official title:

The Effects of Vitamin Supplementation Containing L-Methylfolate (Ocufolin® Forte) on Retinal Venous Pressure and Homocysteine Plasma Levels in Patients With Glaucoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05080153
• Other study ID #: 151119-OcF
• Status: Completed
• Start date: November 15, 2019
• Est. completion date: June 30, 2021

Study information

• Verified date: October 2021
• Source: Devogelaere Vision
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The impact of targeted vitamin supplementation on retinal venous pressure (RVP) and steady state pattern ERG (SSpERG) in patients with RVP 15mmHg or more above intra-ocular pressure (IOP) and serum homocystein 12µmol/l or more, with signs of progression in spite of adequate IOP control, as evidenced by SSpERG abnormality with or without structural progression or visual field progression,

Description:

Provided the inclusion criteria were met, RVP measurement was repeated, and a 1 capsule/day regimen of Ocufolin® forte was subsequently carried out for a duration of 3 months, after which repeat measurements of IOP, SSpERG, and RVP were performed, along with dilated fundoscopy. .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: June 30, 2021
• Est. primary completion date: October 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• glaucoma and/or ocular vascular disease in at least on eye

• abnormal SSpERG

• RVP measured using an ophthalmodynamometer at least 15 mmHg higher than intra-ocular pressure (IOP),

• fasting serum Hcy level > 12 µmol/l

• stable and well-controlled IOP (with or without IOP-lowering treatment)

Exclusion Criteria:

• starting other systemic or ocular medications with potential impacts on RVP within a month before entering the study or during the course of the study

• starting or changing the dosage of other medications with potential impact on SSpERG within 3 months before entering the study or during the course of the study

• non-adherence to the follow-up schedule

• inability to perform a proper RVP measurement using ophthalmodynamometry.

Related Conditions & MeSH terms

• Glaucoma

Intervention

Dietary Supplement:
• Ocufolin forte
start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)

Locations

Country	Name	City	State
Belgium	Devogelaere Vision	Oudenburg

Sponsors (1)

Lead Sponsor	Collaborator
Devogelaere Vision

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	RVP effect	measurement of RVP lowering effect	3 months
Primary	SSpERG effect	measurement of improvement of SSpERG	3 months